The Trevi team is Boston bound. Join Trevi’s President and CEO, Jennifer Good, and CFO, Lisa Delfini at Leerink Partners Therapeutics Forum: I&I and Metabolism. We are excited to connect with investors and discuss Trevi Therapeutics development plans in chronic cough. #healthcare #biotechnology #clinicaltrials #chroniccough #cough
Trevi Therapeutics, Inc.
Biotechnology Research
New Haven, CT 2,675 followers
Clinical-stage biopharmaceutical company
About us
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational oral therapy Haduvio™ (nalbuphine ER). Haduvio’s unique centrally and peripherally active mechanism of action (MOA) has the potential to rebalance the kappa and mu receptors which may play a significant role in chronic cough. Haduvio demonstrated a 75% reduction in daytime cough frequency for idiopathic pulmonary fibrosis (IPF) patients in its Phase 2 Cough And NALbuphine trial. With this positive data, Trevi is focusing future clinical development on chronic cough conditions, including IPF, interstitial lung diseases, and refractory chronic cough. Trevi is headquartered in New Haven, CT.
- Website
-
http://trevitherapeutics.com
External link for Trevi Therapeutics, Inc.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- New Haven, CT
- Type
- Privately Held
- Founded
- 2011
Locations
-
Primary
Get directions
195 Church Street
14th Floor
New Haven, CT 06510, US
Employees at Trevi Therapeutics, Inc.
Updates
-
The Trevi team is traveling this summer. We are pleased to announce our attendance of Leerink Partners Therapeutics Forum: I&I and Metabolism, Oppenheimer & Co. Inc.’s Biotech in the Berkshires and Stifel’s 2024 Biotech Summer Summit. In addition, we are thrilled to announce two abstracts were accepted on our ongoing cough trials. Read more: https://lnkd.in/evwkJxNh Connect with us if you are attending any of these events to continue our discussion on the unmet need in chronic cough and our potential to be a first-in-class therapy for IPF patients suffering with chronic cough. #healthcare #cough #clinicaltrials #biotech
-
-
Learn more about our therapeutic focus in chronic #cough and the current unmet need in #IPF and #RCC, please visit https://ow.ly/M2AM50RuMgX. We are committed to advancing our research for patients in need. Follow our page to see our progress. #clinicaltrials #research #idiopathicpulmonaryfibrosis #RCC
-
-
Reminder: If you are attending Oppenheimer & Co. Inc.’s 2024 Montauk Life Sciences Summit this week, be sure to connect with our CFO Lisa Delfini.
-
-
#Cough is prevalent in ~85% of idiopathic #pulmonaryfibrosis patients and coughing can lead to stigma and isolation. Our dedicated team is focused on moving our development in cough forward for this unmet need. Get the latest updates on our active chronic cough program here: https://ow.ly/sohG50ROqX0
-
-
Please join us in welcoming our Life-Science Sprints in Connecticut summer interns! We’re proud to be one of the 40+ #lifescience companies in #CT to participate in this fantastic #internship program. Learn more: https://lnkd.in/dJEuQw5E
-
-
Our team is made up of adaptive, innovative and hardworking individuals. Every team member, despite their role, is passionate about improving patients’ lives. Learn more about our focus: https://ow.ly/M2O150ROqOQ
-
-
A post hoc analysis of our Ph2a #IPF #cough trial was presented at American Thoracic Society 2024 International Conference. Nalbuphine ER significantly reduced cough bouts compared to placebo. View the full analysis: https://ow.ly/he5q50ROqgf #clinicaltrials #cough #pulmonaryfibrosis
-